CONTE, Pierfranco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 43.291
AS - Asia 18.622
EU - Europa 17.966
SA - Sud America 2.726
AF - Africa 383
OC - Oceania 44
Continente sconosciuto - Info sul continente non disponibili 14
Totale 83.046
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 42.656
GB - Regno Unito 5.584
SG - Singapore 5.397
CN - Cina 5.141
IT - Italia 4.019
HK - Hong Kong 2.276
BR - Brasile 2.102
VN - Vietnam 1.746
SE - Svezia 1.510
DE - Germania 1.298
BD - Bangladesh 1.181
UA - Ucraina 1.118
FI - Finlandia 1.100
IE - Irlanda 930
TR - Turchia 769
RU - Federazione Russa 656
FR - Francia 629
KR - Corea 462
IN - India 425
BG - Bulgaria 397
CA - Canada 314
ID - Indonesia 236
AR - Argentina 206
MX - Messico 163
IQ - Iraq 138
JP - Giappone 127
NL - Olanda 122
EC - Ecuador 98
ZA - Sudafrica 97
PL - Polonia 92
AE - Emirati Arabi Uniti 91
ES - Italia 88
CO - Colombia 82
PK - Pakistan 79
BE - Belgio 78
VE - Venezuela 64
PH - Filippine 60
CL - Cile 58
MY - Malesia 57
UZ - Uzbekistan 53
SA - Arabia Saudita 51
PY - Paraguay 48
MA - Marocco 47
AU - Australia 42
LT - Lituania 42
EG - Egitto 38
CZ - Repubblica Ceca 36
NP - Nepal 36
KE - Kenya 35
AT - Austria 34
JO - Giordania 32
JM - Giamaica 30
TH - Thailandia 30
TN - Tunisia 29
AL - Albania 27
IR - Iran 27
AZ - Azerbaigian 25
ET - Etiopia 25
HU - Ungheria 25
TW - Taiwan 24
UY - Uruguay 24
RO - Romania 23
DZ - Algeria 22
HN - Honduras 22
BO - Bolivia 21
DO - Repubblica Dominicana 21
RS - Serbia 21
CH - Svizzera 20
PE - Perù 20
CR - Costa Rica 19
IL - Israele 19
PT - Portogallo 18
OM - Oman 17
GR - Grecia 16
KZ - Kazakistan 16
LB - Libano 16
NG - Nigeria 16
SN - Senegal 14
SI - Slovenia 13
SK - Slovacchia (Repubblica Slovacca) 12
BH - Bahrain 11
CI - Costa d'Avorio 10
EU - Europa 10
KG - Kirghizistan 10
PA - Panama 10
SY - Repubblica araba siriana 10
TT - Trinidad e Tobago 10
MD - Moldavia 9
NI - Nicaragua 9
PS - Palestinian Territory 9
QA - Qatar 9
AM - Armenia 8
BW - Botswana 8
PR - Porto Rico 8
AO - Angola 7
DK - Danimarca 7
MK - Macedonia 7
NO - Norvegia 7
BA - Bosnia-Erzegovina 6
BB - Barbados 6
Totale 82.923
Salva come PNG Salva come JPEG
Città #
Fairfield 4.174
Southend 3.802
Ashburn 3.727
Singapore 3.493
Woodbridge 3.074
Santa Clara 3.026
Houston 2.627
Jacksonville 2.293
Hong Kong 2.244
Chandler 2.036
Ann Arbor 1.736
Dearborn 1.571
Seattle 1.541
Hefei 1.526
Wilmington 1.521
Cambridge 1.377
San Jose 1.033
Beijing 1.017
London 941
Dublin 924
Nyköping 827
Helsinki 711
Council Bluffs 698
Los Angeles 696
Modena 641
The Dalles 634
Chicago 589
Ho Chi Minh City 582
New York 492
Milan 444
Princeton 444
San Diego 433
Seoul 429
Hanoi 395
Sofia 381
Eugene 379
Izmir 364
Lauterbourg 319
Buffalo 273
Salt Lake City 226
Shanghai 212
Des Moines 206
Moscow 203
Rome 202
Columbus 196
São Paulo 194
Dallas 177
Jakarta 149
Falls Church 142
Munich 138
Boardman 128
Frankfurt am Main 121
Elk Grove Village 116
Tampa 111
Bologna 105
Phoenix 94
Norwalk 93
Naples 90
Tokyo 90
Orem 86
Guangzhou 85
Da Nang 80
Atlanta 73
Haiphong 71
Brussels 70
Turin 68
Miano 66
Toronto 65
Lancaster 64
Denver 63
Chennai 62
Florence 62
Mexico City 62
Warsaw 62
Redwood City 58
Rio de Janeiro 57
Dong Ket 54
Fremont 53
Sterling 53
Belo Horizonte 51
Nanjing 51
Porto Alegre 51
Bremen 49
Kunming 49
Brooklyn 48
Redondo Beach 47
Bari 46
Falkenstein 45
Tashkent 44
Verona 44
Baghdad 41
Brasília 41
Montreal 41
Mumbai 40
Kilburn 38
Miami 38
Stockholm 38
Amsterdam 37
Curitiba 37
Philadelphia 37
Totale 58.634
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.165
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 491
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 444
Rigenerand srl - Spin off Università di Modena e Reggio Emilia 434
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 432
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 430
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 427
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma 422
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 414
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 409
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy 408
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 402
MSC and Tumors: Homing, Differentiation and Secretion Influence The Therapeutic Potentials 393
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 391
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 389
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood 387
Phase I study of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with peritoneal carcinosis 385
Neoadjuvant treatment with Single – Agent Cetuximab Followed by 5-Fu, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer. 382
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 380
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 380
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study 378
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 375
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 374
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 372
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 370
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 363
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 363
Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis 355
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 355
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.. 354
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 354
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM 348
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 347
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 344
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer 342
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 339
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 338
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria 336
Achievements and unmet needs in the management of advanced ovarian cancer 333
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial 331
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer 327
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 325
METHOD FOR PRODUCTION OF ANTI-TUMOR TRAIL PROTEIN 324
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 323
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 320
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy 320
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 320
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. 317
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 316
Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation 316
Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): Is it still a courageous choice? Report of two cases 309
Immune characterization of breast cancer metastases: prognostic implications. 309
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 309
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 309
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 308
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 307
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 307
5-Fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: A randomized phase II study in metastatic colorectal cancer 305
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 299
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. 297
Donor Cell-Derived Osteopoiesis Originates from a Self-Renewing Stem Cell with a Limited Regenerative Contribution after Transplantation 297
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 296
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 296
Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor 291
Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer 291
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. 289
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer 288
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer 283
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting 279
Significance of lymph node sampling in epithelial carcinoma of the ovary. 279
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 276
Prognostic value of "Dworak" tumor regression grade (TRG) after pre-operative chemo-radiotherapy in rectal cancer (RC) 276
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. 273
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 271
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 271
Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A randomized trial of the Gruppo Oncologico Nord Ovest. 268
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of After-6 protocol 1 268
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. 267
Cardiotoxicity of Epirubicin/Paclitaxel Containing Regimens: Role of Cardiac Risk Factors 265
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 265
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 265
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 263
Device for cell culture 261
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 261
Paclitaxel and vinorelbine in anthracycline pretreated breast cancer: a phase II study. 260
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG 259
Biomarkers predicting clinical benefit: fact or fiction? 258
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 258
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 256
The curability of breast cancer and the treatment of advanced disease 256
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. 254
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 254
41. HER2+ EARLY BREAST CANCER: DO WE HAVE ALL THE NECESSARY ANSWERS? 251
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 251
A phase II study with danazol in metastatic breast cancer. 251
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 249
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 248
Biomarker expression and survival after primary chemotherapy for breast cancer. 248
Timing for starting second-line therapy in recurrent ovarian cancer 246
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. 245
Totale 32.986
Salva come PNG Salva come JPEG
Categoria #
all - tutte 316.093
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 316.093
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20226.219 88 931 783 382 147 259 445 325 648 469 962 780
2022/20236.351 741 573 316 510 659 906 77 541 1.521 83 257 167
2023/20243.774 182 248 204 229 705 349 393 705 125 114 163 357
2024/202511.504 362 159 183 872 2.139 1.812 493 761 1.480 780 1.022 1.441
2025/202625.948 1.329 1.003 2.221 3.016 3.369 2.034 2.813 1.440 2.168 2.625 2.172 1.758
2026/2027889 889 0 0 0 0 0 0 0 0 0 0 0
Totale 83.414